Table 2-.
The three prognostic models of AL amyloidosis.
| The prognostic model | Criteria | Survival |
|---|---|---|
| Mayo model 2004 | TnT<0.035 microgram/L NT-pro-BNP < 332 ng/L BNP < 81 ng/L TnI <0.1 microgram/L |
stage 1- median 26.4 months stage 2- median 10.5 months stage 3- median 3.5 months |
| Mayo model 2012 | TnT<0.025 ng/ml NT-pro-BNP < 1800 pg/ml Serum dFLC<180 mg/dL BNP < 400 ng/L TnI- No data |
stage 1- median 94.1 months stage 2- median 40.3 months stage 3- median 14 months stage 4- median 5.8 months |
| European model 2015 | TnT<0.035 ng/ml NT-pro-BNP < 332 pg/ml BNP < 81 ng/L TnI <0.1 microgram/L Mayo stage 3 is subclassified using NT-pro-BNP < 8500 pg/ml |
stage 1- no death cases stage 2– 3 years 52% stage 3a- 3 years 55% stage 3b- 3 years 19% |
| Boston university score 2019 | TnT <0.1 ng/ml BNP < 81 pg/mL |
stage 1- median not reached stage 2- median 9.4 years stage 3a- median 4.3 years stage 3b- median 1 year |
TnT-Troponin T, NT-pro-BNP -N- terminal pro-brain natriuretic peptide, TnI- Troponin I, BNP-brain natriuretic peptide.